0000950170-22-012804.txt : 20220719 0000950170-22-012804.hdr.sgml : 20220719 20220719163611 ACCESSION NUMBER: 0000950170-22-012804 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20220719 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220719 DATE AS OF CHANGE: 20220719 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Inozyme Pharma, Inc. CENTRAL INDEX KEY: 0001693011 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 475129768 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39397 FILM NUMBER: 221091931 BUSINESS ADDRESS: STREET 1: 321 SUMMER STREET STREET 2: SUITE 400 CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 857-330-4340 MAIL ADDRESS: STREET 1: 321 SUMMER STREET STREET 2: SUITE 400 CITY: BOSTON STATE: MA ZIP: 02210 FORMER COMPANY: FORMER CONFORMED NAME: Inozyme Pharma, LLC DATE OF NAME CHANGE: 20161222 8-K 1 inzy-20220719.htm 8-K 8-K
false000169301100016930112022-07-192022-07-19

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): July 19, 2022

 

 

Inozyme Pharma, Inc.

(Exact Name of Registrant as Specified in Charter)

 

 

Delaware

(State or Other Jurisdiction
of Incorporation)

001-39397

(Commission
File Number)

38-4024528

(IRS Employer
Identification No.)

 

321 Summer Street, Suite 400

Boston, Massachusetts

02210

(Address of Principal Executive Offices)

(Zip Code)

 

Registrant’s telephone number, including area code: (857) 330-4340

Not applicable
(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading
symbol(s)

 

Name of each exchange

on which registered

Common stock, par value $0.0001 per share

 

INZY

 

Nasdaq Global Select Market

 

 

 

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 7.01 Regulation FD Disclosure.

 

 

On July 19, 2022, Inozyme Pharma, Inc. (the “Company”) issued a press release announcing preliminary biomarker, safety and pharmacokinetic (“PK”) data from the 0.2 mg/kg dose cohort of the Company’s ongoing Phase 1/2 clinical trial of INZ-701 in adult subjects with ABCC6 Deficiency, which presents as pseudoxanthoma elasticum (“PXE”) in older individuals. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 

Item 8.01 Other Events.

 

 

On July 19, 2022, the Company announced preliminary biomarker, safety and PK data from the 0.2 mg/kg dose cohort of the Company’s ongoing Phase 1/2 clinical trial of INZ-701 in adult subjects with ABCC6 Deficiency, which presents as PXE in older individuals.

 

At the 0.2 mg/kg dose level of INZ-701, all three subjects showed rapid and significant increases in plasma pyrophosphate (“PPi”) levels. In preclinical models, PPi was shown to be a key predictive biomarker of therapeutic benefit in ABCC6 Deficiency.

•
The mean PPi level across the three subjects at baseline was 851 nM.
•
The mean PPi level during the 32-day dose evaluation period across the three subjects was 1057 nM, which was within the range (1002-2169 nM) observed in the Company’s study of healthy subjects (n=10).
•
Among the three subjects, the range of peak PPi levels observed during the 32-day dose evaluation period was 2139-4090 nM.

Preliminary PK and INZ-701 enzymatic activity remained consistent with data previously reported from the Company’s ongoing Phase 1/2 trial of INZ-701 in subjects with ENPP1 Deficiency. INZ-701 continued to exhibit a favorable initial safety profile. INZ-701 was generally well-tolerated with no serious adverse events reported, one grade 1 adverse event (“AE”), and no injection site reactions. The grade 1 AE was not related to INZ-701. Low titers of anti-drug antibodies were observed in one subject at day 32 of the trial, which had no impact on PK or ENPP1 activity. All three subjects from the first cohort enrolled in the open-label Phase 2 48-week extension portion of the trial.

Following the planned review of these preliminary data by a data safety monitoring board, the Company expects to initiate dosing in the next dose cohort (0.6 mg/kg) in this trial in the third quarter of 2022. The Company plans to report topline data from the ongoing Phase 1/2 clinical trial in ABCC6 Deficiency in the first quarter of 2023.

 

Item 9.01 Financial Statements and Exhibits.

 

 

(d) Exhibits

 

 

 

 

Exhibit

No.

 

Description

 

 

 

99.1

 

Press Release, dated July 19, 2022

 

 

 

104

 

Cover Page Interactive Data File (formatted as Inline XBRL)

 

Forward Looking Statements

Statements in this Current Report on Form 8-K about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to trial results, trial design, trial enrollment, trial dosing, the availability of clinical trial data and the potential benefits of INZ-701. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. These risks and uncertainties include, but are not limited to, risks associated with the Company’s ability to conduct its ongoing Phase 1/2 clinical trials of INZ-701 for ENPP1 Deficiency and ABCC6 Deficiency; obtain and maintain necessary approvals from the FDA and other regulatory authorities; continue to advance its product candidates in preclinical studies and clinical trials; replicate in later clinical trials positive results found in preclinical studies and early-stage clinical trials of its product candidates; advance the development of its product candidates under the timelines it anticipates in planned and future clinical trials; obtain, maintain and protect intellectual property rights related to its product candidates; manage expenses; and raise the substantial additional capital needed to achieve its business objectives. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the Company’s actual results to differ from those contained in the forward-looking statements, see the “Risk Factors” section in the Company’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as well as discussions of potential risks, uncertainties and other important factors, in the Company’s most recent filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this Current Report on Form 8-K represent the Company’s views as of the date hereof and should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.

 

 

 

 

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

INOZYME PHARMA, INC.

Date: July 19, 2022

 

By:

 

   /s/ Axel Bolte

 

 

 

 

Name: Axel Bolte

 

 

 

 

Title: President and Chief Executive Officer

 

 

 

 

 

 EX-99.1 2 inzy-ex99_1.htm EX-99.1 EX-99.1

img4202433_0.jpg 

Exhibit 99.1

 

Inozyme Pharma Announces Positive Preliminary Data from Phase 1/2 Clinical Trial of INZ-701 in Subjects with ABCC6 Deficiency (pseudoxanthoma elasticum or PXE)

 

- Rapid and significant increase in plasma pyrophosphate (PPi) levels observed in all three subjects in lowest dose cohort (0.2 mg/kg) –

 

- INZ-701 was generally well-tolerated and exhibited a favorable initial safety profile –

 

- First evidence that INZ-701 increased PPi levels in subjects with functional ENPP1 enzyme -

 

- Dosing in second dose cohort (0.6 mg/kg) expected to commence in the third quarter of 2022 -

 

BOSTON, July 19, 2022 – Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced positive preliminary biomarker, safety, and pharmacokinetic (PK) data from the first three subjects treated in the Phase 1 portion of its ongoing Phase 1/2 clinical trial of INZ-701 in adult subjects with ABCC6 Deficiency, which presents as pseudoxanthoma elasticum (PXE) in older individuals. At the 0.2 mg/kg dose level of INZ-701, all three subjects showed rapid and significant increases in PPi levels. In preclinical models, PPi was shown to be a key predictive biomarker of therapeutic benefit in ABCC6 Deficiency.

 

“The data announced today in subjects with PXE serve as a potential proof of principle that elevation of PPi levels can be achieved in those with functional ENPP1 enzyme,” said Axel Bolte, MSc, MBA, Inozyme’s co-founder, president, and chief executive officer. “ABCC6 Deficiency is a disorder of high unmet medical need with no approved therapies. We are delighted to see that our enzyme replacement therapy, INZ-701, raised PPi levels in subjects with this disorder and believe it has the potential to do so in other disorders that are characterized by low levels of PPi.”

 

Summary of Preliminary Data

 

•
The mean PPi level across the three subjects at baseline was 851 nM.
•
The mean PPi level during the 32-day dose evaluation period across the three subjects was 1057 nM, which was within the range (1002-2169 nM) observed in the Company’s study of healthy subjects (n=10).
•
Among the three subjects, the range of peak PPi levels observed during the 32-day dose evaluation period was 2139-4090 nM.

 

Preliminary PK and INZ-701 enzymatic activity remained consistent with data previously reported from the Company’s ongoing Phase 1/2 trial of INZ-701 in subjects with ENPP1

 

 

Deficiency. INZ-701 continued to exhibit a favorable initial safety profile. INZ-701 was generally well-tolerated with no serious adverse events (SAEs) reported, one grade 1 adverse event (AE), and no injection site reactions. The grade 1 AE was not related to INZ-701. Low titers of anti-drug antibodies (ADAs) were observed in one subject at day 32 of the trial, which had no impact on PK or ENPP1 activity. All three subjects from the first cohort enrolled in the open-label Phase 2 48-week extension portion of the trial.

 

“We continue to be encouraged by the consistent PK data and safety profile of INZ-701 across our two trials and look forward to advancing this trial to the higher dose cohorts”, added Yves Sabbagh, Ph.D., Inozyme’s senior vice president and chief scientific officer.

 

Following the planned review of these preliminary data by a data safety monitoring board (DSMB), Inozyme expects to initiate dosing in the next dose cohort (0.6 mg/kg) in this trial in the third quarter of 2022. The Company plans to report topline data from the ongoing Phase 1/2 clinical trial in ABCC6 Deficiency in the first quarter of 2023.

 

Data shared in this press release and supporting charts can be accessed from the Investor Relations section of Inozyme’s website in the Corporate Presentation file under the News and Events tab.

 

About ABCC6 Deficiency

 

ABCC6 Deficiency is a rare, severe, inherited disorder caused by mutations in the ABCC6 gene, leading to low levels of PPi. PPi is essential for preventing harmful soft tissue calcification and regulating bone mineralization. ABCC6 Deficiency is a systemic and progressively debilitating condition, which affects more than 67,000 individuals worldwide. Infants with ABCC6 Deficiency are diagnosed with generalized arterial calcification of infancy (GACI) type 2, a condition that resembles GACI type 1, the infant form of ENPP1 Deficiency. In older individuals, ABCC6 Deficiency presents as pseudoxanthoma elasticum (PXE), which is characterized by pathological mineralization in blood vessels and soft tissues clinically affecting the skin, eyes, and vascular system. There are no approved therapies for ABCC6 Deficiency.

 

INZ-701 in ABCC6 Deficiency Phase 1/2 Clinical Trial Design

 

The ongoing Phase 1/2 open-label clinical trial is expected to enroll up to nine adult subjects with ABCC6 Deficiency at sites in the United States and Europe. The trial will primarily assess the safety and tolerability of INZ-701 in adult subjects with ABCC6 Deficiency, as well as characterize the pharmacokinetic (PK) and pharmacodynamic (PD) profile of INZ-701, including the evaluation of levels of plasma PPi and other biomarkers. In the Phase 1 dose-escalation portion of the trial, Inozyme is assessing INZ-701 for 32-days at doses of 0.2 mg/kg, 0.6 mg/kg, and 1.8 mg/kg administered via subcutaneous injection twice weekly (after an initial 1-week dosing interval), with three subjects per dose cohort. Doses were selected based on preclinical studies and PK/PD modeling. The Phase 1 dose-escalation portion of the trial seeks to identify a safe, tolerable dose for further development that increases PPi levels. The open-label Phase 2 extension portion of

 

 

the trial will assess long-term safety, pharmacokinetics, and pharmacodynamics of continued treatment with INZ-701 for up to 48 weeks, during which subjects may receive doses of INZ-701 at home depending on site-specific protocols. Exploratory endpoints will include evaluations of vascular, ophthalmologic, and physical function as well as patient-reported outcomes.

 

About INZ-701

 

INZ-701 is a clinical-stage enzyme replacement therapy in development for the treatment of mineralization disorders of the circulatory system, bones, and kidneys. In preclinical studies, the experimental therapy has shown potential to generate PPi and to restore it to appropriate physiological levels, thereby preventing calcification in the vasculature and kidneys, while at the same time normalizing bone mineralization. Inozyme is developing INZ-701 for certain rare, life-threatening, and devastating genetic disorders such as ENPP1 Deficiency and ABCC6 Deficiency in which PPi levels are below the normal physiological levels. INZ-701 is currently in Phase 1/2 clinical trials for the treatment of ENPP1 Deficiency and ABCC6 Deficiency.

 

About Inozyme Pharma

 

Inozyme Pharma, Inc. (Nasdaq: INZY) is a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue, and skeleton. Through our in-depth understanding of the biological pathways involved in mineralization, we are pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. It is well established that two genes, ENPP1 and ABCC6, play key roles in a critical mineralization pathway and that defects in these genes lead to abnormal mineralization. We are initially focused on developing a novel therapy, INZ-701, to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies. INZ-701 is currently in Phase 1/2 clinical trials for the treatment of ENPP1 Deficiency and ABCC6 Deficiency.

 

Inozyme Pharma was founded in 2017 by Joseph Schlessinger, Ph.D., Demetrios Braddock, M.D., Ph.D., and Axel Bolte, MSc, MBA, with technology developed by Dr. Braddock and licensed from Yale University. For more information, please visit www.inozyme.com.

 

Cautionary Note Regarding Forward-Looking Statements

 

Statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to trial results, trial design, trial enrollment, trial dosing, the availability of clinical trial data and the potential benefits of INZ-701. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and

 

 

uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. These risks and uncertainties include, but are not limited to, risks associated with the Company's ability to conduct its ongoing Phase 1/2 clinical trials of INZ-701 for ENPP1 Deficiency and ABCC6 Deficiency; obtain and maintain necessary approvals from the FDA and other regulatory authorities; continue to advance its product candidates in preclinical studies and clinical trials; replicate in later clinical trials positive results found in preclinical studies and early-stage clinical trials of its product candidates; advance the development of its product candidates under the timelines it anticipates in planned and future clinical trials; obtain, maintain, and protect intellectual property rights related to its product candidates; manage expenses; and raise the substantial additional capital needed to achieve its business objectives. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the Company's actual results to differ from those contained in the forward-looking statements, see the "Risk Factors" section in the Company's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as well as discussions of potential risks, uncertainties, and other important factors, in the Company's most recent filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company's views as of the date hereof and should not be relied upon as representing the Company's views as of any date subsequent to the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.

 

Contacts

 

Investors:

Inozyme Pharma

Stefan Riley, Director of Investor Relations

(857) 330-8871
stefan.riley@inozyme.com

 

Media:

SmithSolve

Matt Pera

(973) 886-9150

matt.pera@smithsolve.com

 

 

 GRAPHIC 3 img4202433_0.jpg GRAPHIC begin 644 img4202433_0.jpg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inzy-20220719_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Entity Address, City or Town Entity Address, City or Town Soliciting Material Soliciting Material Entity Ex Transition Period Entity Ex Transition Period Amendment Flag Amendment Flag Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code City Area Code City Area Code Document Period End Date Document Period End Date Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity File Number Entity File Number Entity Address, Address Line One Entity Address, Address Line One Entity Tax Identification Number Entity Tax Identification Number Entity Emerging Growth Company Entity Emerging Growth Company Entity Registrant Name Entity Registrant Name Pre-commencement Tender Offer Pre-commencement Tender Offer Title of 12(b) Security Title of 12(b) Security Entity Address, State or Province Entity Address, State or Province Document Type Document Type Written Communications Written Communications Security Exchange Name Security Exchange Name Entity Address, Address Line Two Entity Address, Address Line Two Entity Central Index Key Entity Central Index Key Local Phone Number Local Phone Number Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Cover [Abstract] Trading Symbol Trading Symbol EX-101.PRE 5 inzy-20220719_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.SCH 6 inzy-20220719.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.2
Document And Entity Information
Jul. 19, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jul. 19, 2022
Entity Registrant Name Inozyme Pharma, Inc.
Entity Central Index Key 0001693011
Entity Emerging Growth Company true
Entity Ex Transition Period false
Entity File Number 001-39397
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 38-4024528
Entity Address, Address Line One 321 Summer Street
Entity Address, Address Line Two Suite 400
Entity Address, City or Town Boston
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02210
City Area Code 857
Local Phone Number 330-4340
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock, par value $0.0001 per share
Trading Symbol INZY
Security Exchange Name NASDAQ
XML 8 inzy-20220719_htm.xml IDEA: XBRL DOCUMENT 0001693011 2022-07-19 2022-07-19 false 0001693011 8-K 2022-07-19 Inozyme Pharma, Inc. DE 001-39397 38-4024528 321 Summer Street Suite 400 Boston MA 02210 857 330-4340 false false false false Common stock, par value $0.0001 per share INZY NASDAQ true false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2 html 1 24 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://www.inozyme.com/20220719/taxonomy/role/Role_DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports inzy-20220719.htm inzy-20220719.xsd inzy-20220719_lab.xml inzy-20220719_pre.xml inzy-ex99_1.htm http://xbrl.sec.gov/dei/2022 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "inzy-20220719.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "inzy-20220719.htm" ] }, "labelLink": { "local": [ "inzy-20220719_lab.xml" ] }, "presentationLink": { "local": [ "inzy-20220719_pre.xml" ] }, "schema": { "local": [ "inzy-20220719.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "inzy", "nsuri": "http://www.inozyme.com/20220719", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "inzy-20220719.htm", "contextRef": "C_e4623d74-e248-41ce-8baf-87255a5c2bcf", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document And Entity Information", "role": "http://www.inozyme.com/20220719/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "inzy-20220719.htm", "contextRef": "C_e4623d74-e248-41ce-8baf-87255a5c2bcf", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.inozyme.com/20220719/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.inozyme.com/20220719/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.inozyme.com/20220719/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.inozyme.com/20220719/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.inozyme.com/20220719/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.inozyme.com/20220719/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.inozyme.com/20220719/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.inozyme.com/20220719/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.inozyme.com/20220719/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.inozyme.com/20220719/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.inozyme.com/20220719/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.inozyme.com/20220719/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.inozyme.com/20220719/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.inozyme.com/20220719/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.inozyme.com/20220719/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.inozyme.com/20220719/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.inozyme.com/20220719/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.inozyme.com/20220719/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.inozyme.com/20220719/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.inozyme.com/20220719/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.inozyme.com/20220719/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.inozyme.com/20220719/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.inozyme.com/20220719/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.inozyme.com/20220719/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 15 0000950170-22-012804-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-22-012804-xbrl.zip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end